<DOC>
	<DOCNO>NCT00432328</DOCNO>
	<brief_summary>Severe scar common problem follow breast reduction surgery , study show 64 % patient develop hypertrophic scar three month operation . Scar severity influence large number factor include age , sex , skin thickness tension , ethnicity position scar body . Therefore sensitive reliable method ass efficacy anti-scarring treatment compare bilateral wound individual . Bilateral breast reduction surgery provide ideal model within patient evaluation anti-scarring activity wound develop bad scar . This study undertaken investigate efficacy safety Juvista ( give intradermal injection 200ng per 1cm wound margin ) reduction scar appearance apply approximate wound margin follow bilateral reduction mammaplasty .</brief_summary>
	<brief_title>Juvista ( Avotermin ) Breast Reduction Surgery Scars</brief_title>
	<detailed_description />
	<mesh_term>Cicatrix</mesh_term>
	<criteria>Female patient 18 65 year age undergoing bilateral reduction mammaplasty anchor shape incision , give write informed consent . Patients Body Mass Index 1532 kg/m2 inclusive . Patients child bear potential use method ( ) contraception acceptable Investigator agree least screening visit 1 month administration trial investigational product . Patients , opinion Investigator , clinically acceptable result laboratory test specify trial protocol . Patients significant breast asymmetry may result asymmetrical operative incision make leave right breast . Patients breast asymmetry may result different postoperative tension wound leave right breast . Patients surgery area incise within one year trial surgery . Patients history bleed disorder . Patients history breast malignancy . Patients skin disorder chronic currently active Investigator considers adversely affect heal wound involve area examine trial . Patients direct question and/or physical examination , evidence past present clinically significant medical condition would impair wound heal . Patients history clinically significant hypersensitivity drug surgical dressing use trial . Patients take , take , investigational drug 3 month prior screen visit . Patients take regular , continuous , oral corticosteroid therapy . Patients undergoing investigation change management exist medical condition . Patients become pregnant include day surgery lactating . Patients diseases condition could , opinion Investigator , interfere assessment safety efficacy investigational product . Patients , opinion Investigator , likely complete trial .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2009</verification_date>
</DOC>